Terms: = Prostate cancer AND RUNX1T1, ENSG00000079102, 862 AND Diagnosis
25 results:
1. European cancer mortality predictions for the year 2023 with focus on lung cancer.
Malvezzi M; Santucci C; Boffetta P; Collatuzzo G; Levi F; La Vecchia C; Negri E
Ann Oncol; 2023 Apr; 34(4):410-419. PubMed ID: 36882139
[TBL] [Abstract] [Full Text] [Related]
2. Serum organic acid metabolites can be used as potential biomarkers to identify prostatitis, benign prostatic hyperplasia, and prostate cancer.
He J; Han Z; Luo W; Shen J; Xie F; Liao L; Zou G; Luo X; Guo Z; Li Y; Li J; Chen H
Front Immunol; 2022; 13():998447. PubMed ID: 36685547
[TBL] [Abstract] [Full Text] [Related]
3. Applying a genetic risk score for prostate cancer to men with lower urinary tract symptoms in primary care to predict prostate cancer diagnosis: a cohort study in the UK Biobank.
Green HD; Merriel SWD; Oram RA; Ruth KS; Tyrrell J; Jones SE; Thirlwell C; Weedon MN; Bailey SER
Br J Cancer; 2022 Nov; 127(8):1534-1539. PubMed ID: 35978138
[TBL] [Abstract] [Full Text] [Related]
4. Causes of Death after prostate cancer diagnosis: A Population-Based Study.
Guo Y; Dong X; Mao S; Yang F; Wang R; Ma W; Liu J; Li C; Zheng Z; Zhang W; Zhang A; Yao X
Oxid Med Cell Longev; 2022; 2022():8145173. PubMed ID: 35502209
[TBL] [Abstract] [Full Text] [Related]
5. Urinary hsv2-miR-H9 to hsa-miR-3659 ratio is an effective marker for discriminating prostate cancer from benign prostate hyperplasia in patients within the prostate-specific antigen grey zone.
Kang HW; Byun YJ; Moon SM; Kim K; Piao XM; Zheng CM; Moon SK; Choi YH; Kim WT; Kim YJ; Lee SC; Yun SJ; Kim WJ
Investig Clin Urol; 2022 Mar; 63(2):238-244. PubMed ID: 35244999
[TBL] [Abstract] [Full Text] [Related]
6. Artificial intelligence for diagnosis and Gleason grading of prostate cancer: the PANDA challenge.
Bulten W; Kartasalo K; Chen PC; Ström P; Pinckaers H; Nagpal K; Cai Y; Steiner DF; van Boven H; Vink R; Hulsbergen-van de Kaa C; van der Laak J; Amin MB; Evans AJ; van der Kwast T; Allan R; Humphrey PA; Grönberg H; Samaratunga H; Delahunt B; Tsuzuki T; Häkkinen T; Egevad L; Demkin M; Dane S; Tan F; Valkonen M; Corrado GS; Peng L; Mermel CH; Ruusuvuori P; Litjens G; Eklund M;
Nat Med; 2022 Jan; 28(1):154-163. PubMed ID: 35027755
[TBL] [Abstract] [Full Text] [Related]
7. Impact of diverticular disease on prostate cancer risk among hypertensive men.
Tomer N; Chakravarty D; Ratnani P; Mohamed NE; Jambor I; Dovey Z; Palese MA; Tewari AK
Prostate Cancer Prostatic Dis; 2022 Apr; 25(4):700-706. PubMed ID: 34621012
[TBL] [Abstract] [Full Text] [Related]
8. Population-Level Uptake of Moderately Hypofractionated Definitive Radiation Therapy in the Treatment of prostate cancer.
Nithiyananthan K; Creighton N; Currow D; Martin JM
Int J Radiat Oncol Biol Phys; 2021 Oct; 111(2):417-423. PubMed ID: 33974884
[TBL] [Abstract] [Full Text] [Related]
9. prostate cancer Risk Calculator Apps in a Taiwanese Population Cohort: Validation Study.
Chen IA; Chu CH; Lin JT; Tsai JY; Yu CC; Sridhar AN; Sooriakumaran P; Loureiro RCV; Chand M
J Med Internet Res; 2020 Dec; 22(12):e16322. PubMed ID: 33337340
[TBL] [Abstract] [Full Text] [Related]
10. Detection and dynamics of circulating tumor cells in patients with high-risk prostate cancer treated with radiotherapy and hormones: a prospective phase II study.
Zapatero A; Gómez-Caamaño A; Cabeza Rodriguez MÁ; Muinelo-Romay L; Martin de Vidales C; Abalo A; Calvo Crespo P; Leon Mateos L; Olivier C; Vega Piris LV
Radiat Oncol; 2020 Jun; 15(1):137. PubMed ID: 32487218
[TBL] [Abstract] [Full Text] [Related]
11. Evaluation of the most optimal multiparametric magnetic resonance imaging sequence for determining pathological length of capsular contact.
Onay A; Vural M; Armutlu A; Ozel Yıldız S; Kiremit MC; Esen T; Bakır B
Eur J Radiol; 2019 Mar; 112():192-199. PubMed ID: 30777210
[TBL] [Abstract] [Full Text] [Related]
12. Diagnostic value of combined IQGAP3/BMP4 and IQGAP3/FAM107A expression ratios in urinary cell-free DNA for discriminating bladder cancer from hematuria.
Xu Y; Kim YH; Jeong P; Piao XM; Byun YJ; Kang HW; Kim WT; Lee JY; Kim IY; Moon SK; Choi YH; Yun SJ; Kim WJ
Urol Oncol; 2019 Jan; 37(1):86-96. PubMed ID: 30446454
[TBL] [Abstract] [Full Text] [Related]
13. An initial melanoma diagnosis may increase the subsequent risk of prostate cancer: Results from the New South Wales cancer Registry.
Cole-Clark D; Nair-Shalliker V; Bang A; Rasiah K; Chalasani V; Smith DP
Sci Rep; 2018 May; 8(1):7167. PubMed ID: 29740153
[TBL] [Abstract] [Full Text] [Related]
14. Association between metformin use and mortality in patients with type 2 diabetes mellitus and localized resectable pancreatic cancer: a nationwide population-based study in korea.
Jang WI; Kim MS; Kang SH; Jo AJ; Kim YJ; Tchoe HJ; Park CM; Kim HJ; Choi JA; Choi HJ; Paik EK; Seo YS; Yoo HJ; Kang JK; Han CJ; Kim YJ; Kim SB; Ko MJ
Oncotarget; 2017 Feb; 8(6):9587-9596. PubMed ID: 28077783
[TBL] [Abstract] [Full Text] [Related]
15. MRI assessment of pathological stage and surgical margins in anterior prostate cancer (APC) using subjective and quantitative analysis.
Schieda N; Lim CS; Idris M; Lim RS; Morash C; Breau RH; Flood TA; McInnes MDF
J Magn Reson Imaging; 2017 May; 45(5):1296-1303. PubMed ID: 27726247
[TBL] [Abstract] [Full Text] [Related]
16. Increased Fall Risk in Patients Receiving Androgen Deprivation Therapy for prostate cancer.
Wu FJ; Sheu SY; Lin HC; Chung SD
Urology; 2016 Sep; 95():145-50. PubMed ID: 27318262
[TBL] [Abstract] [Full Text] [Related]
17. Head-to-head comparison of PI-RADS v2 and PI-RADS v1.
Polanec S; Helbich TH; Bickel H; Pinker-Domenig K; Georg D; Shariat SF; Aulitzky W; Susani M; Baltzer PA
Eur J Radiol; 2016 Jun; 85(6):1125-31. PubMed ID: 27161062
[TBL] [Abstract] [Full Text] [Related]
18. Differential post-prostatectomy cancer-specific survival of occult T3 vs. clinical T3 prostate cancer: Implications for managing patients upstaged on prostate magnetic resonance imaging.
Muralidhar V; Dinh KT; Mahal BA; Ziehr DR; Chen YW; Viswanathan VB; Nezolosky MD; Choueiri TK; Hoffman KE; Hu JC; Sweeney CJ; Trinh QD; Nguyen PL
Urol Oncol; 2015 Jul; 33(7):330.e19-25. PubMed ID: 25990612
[TBL] [Abstract] [Full Text] [Related]
19. Gleason Upgrading with Time in a Large prostate cancer Active Surveillance Cohort.
Jain S; Loblaw A; Vesprini D; Zhang L; Kattan MW; Mamedov A; Jethava V; Sethukavalan P; Yu C; Klotz L
J Urol; 2015 Jul; 194(1):79-84. PubMed ID: 25660208
[TBL] [Abstract] [Full Text] [Related]
20. The economic burden of prostate cancer.
Roehrborn CG; Black LK
BJU Int; 2011 Sep; 108(6):806-13. PubMed ID: 21884356
[TBL] [Abstract] [Full Text] [Related]
[Next]
